ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

netakimab

Its studies are mostly in Psoriasis · Spondylitis, Ankylosing, led by 2 companies.

Drug pageNetakimab: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 28, 20253 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SPH-BIOCAD (HK)its history only20 open or runningphase 3since May 28, 2025May 28, 2025none ahead
Biocad11 open or runningphase 3since Oct 11, 2024Oct 11, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biocad only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named netakimabINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Oct 11, 2024First study: phase 3 study in Plaque PsoriasisFirst studyNCT06640517 · 140 enrolled · Russia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Biocad leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06640517Plaque Psoriasis · Russia3Active, not recruitingJun 2026140

How it is read

Names in the registry

  • “Netakimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.